Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9639948 | 1.00 | NPSR1 (0.58) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL136952 | 1.00 | NPSR1 (0.58) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL9640847 | 0.86 | NPSR1 (0.54) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL3289399 | 0.86 | NPSR1 (0.54) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL3289401 | 0.86 | NPSR1 (0.54) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL10532252 | 0.86 | ALDH1A1 (0.44) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL11126166 | 0.84 | NPSR1 (0.52) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL11818474 | 0.82 | — | — | |
| SCHEMBL6127444 | 0.82 | — | — | |
| SCHEMBL17300447 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138979-A1 | PROCESSES FOR PREPARING KRAS INHIBITORS | INCYTE CORP (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026090336-A1 | PROCESSES FOR PREPARING KRAS INHIBITORS | INCYTE CORPORATION (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250304601-A1 | Processes for Preparing KRAS Inhibitors | INCYTE CORPORATION | 2025-10-02 | — | — | US | disclosed |
| WO-2025080589-A1 | PROCESSES FOR PREPARING KRAS INHIBITORS | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-116507337-A | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4192836-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-11453675-B2 | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-09-27 | — | — | US | disclosed |
| WO-2022028598-A1 | ATR INHIBITORS AND USES THEREOF | SHANGHAI ANTENGENE CORPORATION LIMITED (CN) | 2022-02-10 | — | — | WO | disclosed |
| WO-1996024343-A1 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-15 | — | — | WO | disclosed |
| WO-1993013104-A1 | C.N.S. ACTIVE TRICYCLIC THIENOPYRIDINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
| EP-0327223-B1 | ANXIOLYTIC AND ANTIDEPRESSANT TETRAHYDROBENZOTHIENOPYRIDINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1993-06-02 | — | — | EP | disclosed |
| US-5100897-A | Hypotensive agents, congestive heart failure, ocular hypertension | MERCK & CO., INC. (US) | 1992-03-31 | — | — | US | disclosed |
| US-5093493-A | Anxiolytic agents, antidepressants | BEECHAM GROUP P.L.C. (GB) | 1992-03-03 | — | — | US | disclosed |
| EP-0419048-A2 | Substituted pyrimidinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| EP-0327223-A1 | Anxiolytic and antidepressant tetrahydrobenzothienopyridine derivatives | BEECHAM GROUP PLC (GB) | 1989-08-09 | — | — | EP | disclosed |
| US-4855320-A | ANTICONVULSANTS, ANTIEPILEPTICS | DR. WILLMAR SCHWABE GMBH & COMPANY (DE) | 1989-08-08 | — | — | US | disclosed |
| EP-0126970-A2 | Anxiolytic and anti-depressant thienopyridine derivatives | BEECHAM GROUP PLC (GB) | 1984-12-05 | — | — | EP | disclosed |
| US-3950427-A | ANTIINFLAMMATORY, ANTIPYRETIC | BOEHRINGER INGELHEIM GMBH (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304601-A1 | Processes for Preparing KRAS Inhibitors | KRAS, NRAS, HRAS | NPSR1 4640/4885HCAR2 4819/4885ALDH1A1 3367/4885 |
| US-11453675-B2 | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | GBA1, GAA, GBA2 | NPSR1 3423/4885HCAR2 2716/4885ALDH1A1 1121/4885 |
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ATR, CHEK1, CHEK2 | NPSR1 4812/4885HCAR2 4620/4885ALDH1A1 4462/4885 |
| US-20260138979-A1 | PROCESSES FOR PREPARING KRAS INHIBITORS | KRAS, NRAS, HRAS | NPSR1 4681/4885HCAR2 3550/4885ALDH1A1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.